Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: A prospective and randomized study

Japanese Journal of Clinical Oncology

Volumn 30, Issue 3, 2000, Pages 131-136

  Akaza, Hideyuki ^a   Homma, Yukio ^b   Okada, Kiyoki ^c   Yokoyama, Masao ^d   Moriyama, Nobuo ^b   Usami, Michiyuki ^e   Hirao, Yoshihiko ^f   Tsushima, Tomoyasu ^g   Ohashi, Yasuo ^b   Yoshio, Aso ^h  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f NARA MEDICAL UNIVERSITY   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

^h FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

Author keywords

Control study; Hormone therapy; LH RH agonist; Localized or locally advanced prostate cancer; Randomized

Indexed keywords

CHLORMADINONE ACETATE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SURGICAL RISK;

EID: 0034033665     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyd035     Document Type: Article

References (17)

1. Akaza H, Usami M, Koiso K, Kotake T, Aso Y, Niijima T, et al. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostate cancer. Jpn J Clin Oncol 1992;22:177-84.
2. Smith JA, Glode LM, Max DT, Wettlaufer JN, Anber D, Stein BS, et al. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology 1985;25:106-14.
3. Akaza H, Isaka S, Usami M, Kanetake H, Kotake T, Koiso K, et al. Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. Int J Urol 1996;3:468-71.
4. Denis LJ, Keuppens F, Smith PH, Whelan P, Carnerio de Moura JL, Newling D, et al. Maximum androgen blockade: final analysis of EORTC phase III trial 30853. Eur Urol 1998;33:144-51.
5. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprorelin with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
6. Fourcade RO, Chatelain C. Androgen deprivation for prostatic carcinoma: a rationale for choosing compounds. Int J Urol 1998;5:303-11.
7. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997;50:330-6.
8. Japanese Urological Association and Japanese Pathological Society. General Rules for Clinical and Pathological Studies on Prostatic Cancer, 2nd ed. Tokyo: Kanehara 1992 (in Japanese).
9. Walsh PC, Partin AW, Esptein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6.
10. Gibbons RP, Correa RJ, Brannen GE, Weissman RM. Total prostatectomy for clinically localized prostate cancer: long-term results. J Urol 1989;141:564-6.
11. Lepor H, Kimball AW, Walsh PC. Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol 1989;141:82-4.
12. Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, et al. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. Int J Urol 1999;6:229-37.
13. Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, et al. Preoperative endocrine therapy for clinical stage A2, B and C prostate cancer: an interim report on short-term effects. Int J Urol 1997;4:144-51.
14. Usami M, Kotake T, Akaza H, Koiso K, Homma Y, Kawabe K, et al. The effect of chlormadinone acetate or fosfestrol on the LH-RH agonist-based treatment of advanced prostate cancer. Hinyoki Geka 1998;11:759-72 (in Japanese).
15. Wasson JH, Fowler FJ, Barry MJ. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. J Urol 1998;159:1993-7.
16. Johansson JE, Adami HO, Anderson SO, Bergstorm R, Holmberg L, Krusemo UB. High 10 year survival rate in patients with early, untreated prostate cancer. J Am Med Assoc 1992;267:2191-6.
17. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 1998;82:342-8.